Comment
Author: Admin | 2025-04-28
Otherwise directed by a clinician. For self-medication in adolescents ≥12 years of age, maximum 1.2 g daily. Self-medication should not exceed 3 days unless otherwise directed by a clinician.IVFor children 6 months to For adolescents 12–17 years of age, maximum 2.4 g per 24-hour period.DysmenorrheaOralFor self-medication in adolescents 12–17 years of age, maximum 1.2 g daily.AdultsInflammatory DiseasesOsteoarthritis or Rheumatoid ArthritisOralMaximum 3.2 g daily.PainOralFor mild to moderate pain, maximum 3.2 g daily.In fixed combination with hydrocodone, maximum 1 g of ibuprofen daily.For self-medication of minor aches and pain, maximum 1.2 g daily. Self-medication should not exceed 10 days unless otherwise directed by a clinician.In fixed combination with acetaminophen for self-medication of minor aches and pains, maximum 250 mg of ibuprofen every 8 hours. Self-medication should not exceed 10 days unless otherwise directed by a clinician.For self-medication of migraine pain, maximum 400 mg in a 24-hour period unless otherwise directed by a clinician.IVMaximum 3.2 g in a 24-hour period.DysmenorrheaOralMaximum 3.2 g daily.For self-medication, maximum 1.2 g daily.FeverOralFor self-medication, maximum 1.2 g daily. Self-medication should not exceed 3 days unless otherwise directed by a clinician.IVMaximum 3.2 g in a 24-hour period.Special PopulationsRenal ImpairmentAvoid use in patients with advanced renal disease unless benefits expected to outweigh risk of worsening renal function. (See Renal Impairment under Cautions.)CYP2C9 Poor or Intermediate MetabolizersCYP2C9 poor metabolizers: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend initiating ibuprofen at a dosage that is 25–50% of the lowest recommended initial dosage and cautiously titrating to a clinically effective dosage, up to a dosage that is 25–50% of the maximum recommended dosage. Do not increase dosage until steady-state concentrations are attained (≥5 days after initial dose). Alternatively, consider a drug that is not metabolized by CYP2C9 or is not substantially affected by CYP2C9 genetic variants in vivo. (See Pharmacogenomic Considerations under Cautions.)CYP2C9 intermediate metabolizers with a diplotype functional activity score (AS) of 1: CPIC guidelines recommend initiating ibuprofen at the lowest recommended initial dosage and cautiously titrating to a clinically effective dosage, up to the maximum recommended dosage.Intermediate metabolizers with an AS of 1.5 may receive dosages recommended for normal metabolizers.CPIC dosage recommendations
Add Comment